Keyword: Acadia Pharmaceuticals
Achillion appoints Joseph Truitt after CEO steps down; Lilly hires Leena Gandhi to lead new I-O team; and C4 promotes Andrew Phillips to CEO.
The new “Parkinson’s Clinical Trial Companion” education suite has two parts: one for potential participants and the other for researchers.
Teva’s former chairman Peterburg resigns, OrbiMed founder Isaly steps down, Grail poaches Roche exec Cook as CEO.
Impax, Alexion and Depomed all have their own problems to worry about, and they're all counting on the new CEOs they just tapped to turn the situation around.
Upon its April approval, Acadia’s Nuplazid became the first drug that works by targeting 5-HT2A receptors, providing an advance for Parkinson’s patients who suffer from hallucinations or delusions.
Acadia Pharmaceuticals has won its lengthy quest to gain an approval for Nuplazid (pimavanserin), a breakthrough antipsychotic.